RU2001133342A - Новое применение 1[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина и его физиологически приемлемых солей - Google Patents
Новое применение 1[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина и его физиологически приемлемых солейInfo
- Publication number
- RU2001133342A RU2001133342A RU2001133342/14A RU2001133342A RU2001133342A RU 2001133342 A RU2001133342 A RU 2001133342A RU 2001133342/14 A RU2001133342/14 A RU 2001133342/14A RU 2001133342 A RU2001133342 A RU 2001133342A RU 2001133342 A RU2001133342 A RU 2001133342A
- Authority
- RU
- Russia
- Prior art keywords
- carbamoylbenzofuran
- cyanoindol
- piperazine
- butyl
- physiologically acceptable
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 11
- 239000011780 sodium chloride Substances 0.000 title claims 11
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 title claims 10
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 206010057666 Anxiety disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 206010016279 Fear of open space Diseases 0.000 claims 2
- -1 5-cyanoindol-3-yl Chemical group 0.000 claims 1
- 206010004938 Bipolar disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033666 Panic disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 230000037328 acute stress Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 201000006180 eating disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000001880 sexual dysfunction Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Claims (10)
1. Применение 1-[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина или его физиологически приемлемой соли в производстве медицинских препаратов для лечения субтипа тревожных расстройств, выбранных из субтипов панического расстройства сопряженного или не сопряженного с боязнью открытого пространства, собственно боязни открытого пространства, навязчиво-маниакальных симптоматических расстройств, социальной фобии, расстройства типа посттравматического стресса, проявлений острого стресса и/или общетревожного расстройства.
2. Фармацевтический препарат для лечения субтипа тревожных расстройств по п.1, отличающийся тем, что он содержит, по крайней мере, 1-[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазин или одну из его фармацевтически приемлемых солей.
3. Применение-[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина или его физиологически приемлемой соли в производстве медицинских препаратов для лечения биполярных расстройств.
4. Применение-[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина или его физиологически приемлемой соли в производстве медицинских препаратов для лечения мании.
5. Применение-[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина или его физиологически приемлемой соли в производстве медицинских препаратов для лечения слабоумия.
6. Применение-[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина или его физиологически приемлемой соли в производстве медицинских препаратов для лечения вызываемых веществами расстройств.
7. Применение-[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина или его физиологически приемлемой соли в производстве медицинских препаратов для лечения половых дисфункций.
8. Применение-[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина или его физиологически приемлемой соли в производстве медицинских препаратов для лечения пищевых расстройств, отсутствия аппетита или ожирения.
9. Применение-[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина или его физиологически приемлемой соли в производстве медицинских препаратов для лечения фибромиальгии.
10. Применение по п.1 и пп.3-9 в случае, когда фармакологически приемлемой солью является гидрохлорид 1-[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99109295 | 1999-05-27 | ||
| EP99109295.8 | 1999-05-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2001133342A true RU2001133342A (ru) | 2003-08-27 |
| RU2237477C2 RU2237477C2 (ru) | 2004-10-10 |
Family
ID=8238153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001133342A RU2237477C2 (ru) | 1999-05-27 | 2000-05-16 | Новое применение 1[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина и его физиологически приемлемых солей |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US6900212B1 (ru) |
| EP (3) | EP1185272B1 (ru) |
| JP (2) | JP4884588B2 (ru) |
| KR (1) | KR100683367B1 (ru) |
| CN (3) | CN101869565A (ru) |
| AR (1) | AR024112A1 (ru) |
| AT (3) | ATE337008T1 (ru) |
| AU (1) | AU771778B2 (ru) |
| BR (1) | BR0010948A (ru) |
| CA (3) | CA2694866A1 (ru) |
| CY (2) | CY1105750T1 (ru) |
| CZ (1) | CZ295623B6 (ru) |
| DE (3) | DE60042710D1 (ru) |
| DK (3) | DK1185272T3 (ru) |
| ES (3) | ES2271707T3 (ru) |
| HK (1) | HK1048444B (ru) |
| HU (1) | HU229059B1 (ru) |
| IL (2) | IL146707A0 (ru) |
| MX (1) | MXPA01012172A (ru) |
| MY (1) | MY135627A (ru) |
| NO (2) | NO322120B1 (ru) |
| PL (3) | PL200490B1 (ru) |
| PT (3) | PT1185272E (ru) |
| RU (1) | RU2237477C2 (ru) |
| SI (2) | SI1410800T1 (ru) |
| SK (1) | SK287851B6 (ru) |
| TR (1) | TR200103361T2 (ru) |
| TW (1) | TW518218B (ru) |
| UA (1) | UA74337C2 (ru) |
| WO (1) | WO2000072832A2 (ru) |
| ZA (1) | ZA200110485B (ru) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| UA76130C2 (en) * | 2000-11-20 | 2006-07-17 | Merck Patent Gmbh | Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome |
| DE10112151A1 (de) | 2001-03-14 | 2002-09-19 | Merck Patent Gmbh | Substituierte Benzofuran-2-carbonsäureamide |
| UA76758C2 (ru) * | 2001-06-19 | 2006-09-15 | Мерк Патент Гмбх | Полиморфные формы гидрохлорида 1-[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина |
| DE10217006A1 (de) * | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
| DE10305739A1 (de) | 2003-02-11 | 2004-08-19 | Merck Patent Gmbh | Benzofuranderivate |
| WO2004082686A2 (en) * | 2003-03-13 | 2004-09-30 | Dynogen Pharmaceuticals, Inc. | Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction |
| US7893261B2 (en) | 2004-03-26 | 2011-02-22 | Baylor University | Serotonin reuptake inhibitors |
| MX2008015226A (es) | 2006-05-30 | 2008-12-12 | Astrazeneca Ab | Derivados de 1,3,4-oxadiazol como inhibidores de dgat1. |
| BRPI0821274A2 (pt) | 2007-12-20 | 2017-06-13 | Astrazeneca Ab | composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica |
| EP2443096A1 (en) | 2009-06-19 | 2012-04-25 | AstraZeneca AB | Pyrazine carboxamides as inhibitors of dgat1 |
| RU2556585C2 (ru) | 2009-11-06 | 2015-07-10 | Ск Биофармасъютиклс Ко., Лтд. | Способы лечения синдрома дефицита внимания и гиперактивности |
| CN102781436B (zh) | 2009-11-06 | 2014-01-08 | 爱思开生物制药株式会社 | 纤维肌痛综合征的治疗方法 |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| EP2688884A1 (en) | 2011-03-20 | 2014-01-29 | Cadila Healthcare Limited | Amorphous form of vilazodone hydrochloride and process for its preparation |
| CN102949364A (zh) * | 2011-08-30 | 2013-03-06 | 天津药物研究院 | 一种含有效成分盐酸维拉佐酮的缓释片 |
| EP2861586A4 (en) | 2012-06-13 | 2015-11-11 | Apotex Inc | FORMS OF VILAZODONE AND METHODS OF PREPARATION THEREOF |
| CN102860993A (zh) * | 2012-10-16 | 2013-01-09 | 北京诚创思达医药科技有限公司 | 一种盐酸维拉唑酮快速释放片剂及其制备方法 |
| WO2014064715A2 (en) | 2012-10-22 | 2014-05-01 | Cadila Healthcare Limited | Amorphous form of vilazodone hydrochloride and process for preparing thereof |
| CN102977083A (zh) * | 2012-12-17 | 2013-03-20 | 南京海纳医药科技有限公司 | 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法 |
| EP3598971B1 (en) | 2013-01-22 | 2024-03-20 | Vistagen Therapeutics, Inc. | Dosage forms and therapeutic uses of l-4-chlorokynurenine |
| EP2824104A1 (en) | 2013-07-12 | 2015-01-14 | Sandoz AG | Process for the preparation of form III of Vilazodone hydrochloride |
| EP3297619B1 (en) * | 2015-05-22 | 2022-07-06 | Vistagen Therapeutics, Inc. | Therapeutic uses of l-4-chlorokynurenine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4333254A1 (de) | 1993-09-30 | 1995-04-06 | Merck Patent Gmbh | Piperidine und Piperazine |
| GB9406857D0 (en) * | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| DE19514567A1 (de) | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Benzofurane |
| US5763457A (en) * | 1995-11-13 | 1998-06-09 | Eli Lilly And Company | Method for treating anxiety |
| US5914394A (en) * | 1997-03-27 | 1999-06-22 | Millenium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| US5900420A (en) * | 1997-06-19 | 1999-05-04 | Cole; William L. | Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
| US6470933B1 (en) * | 1998-03-09 | 2002-10-29 | Pirelli Pneumatici S.P.A. | Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire |
| FR2781671A1 (fr) * | 1998-07-28 | 2000-02-04 | Synthelabo | Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique |
| TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| EP1291660A3 (en) * | 2001-09-11 | 2003-05-28 | Koyo Seiko Co., Ltd. | Magnetic pulser ring, magnetizing device and method, and bearing unit having a magnetic pulser ring |
| FR2844591B1 (fr) * | 2002-09-13 | 2005-04-15 | Arvinmeritor Light Vehicle Sys | Dispositif de determination du deplacement d'un arbre |
-
1999
- 1999-11-15 TW TW088119882A patent/TW518218B/zh not_active IP Right Cessation
-
2000
- 2000-05-16 AT AT04001441T patent/ATE337008T1/de active
- 2000-05-16 PL PL383006A patent/PL200490B1/pl unknown
- 2000-05-16 DK DK00935031T patent/DK1185272T3/da active
- 2000-05-16 MX MXPA01012172A patent/MXPA01012172A/es active IP Right Grant
- 2000-05-16 KR KR1020017015141A patent/KR100683367B1/ko not_active IP Right Cessation
- 2000-05-16 ES ES04001441T patent/ES2271707T3/es not_active Expired - Lifetime
- 2000-05-16 CA CA2694866A patent/CA2694866A1/en not_active Abandoned
- 2000-05-16 AU AU50663/00A patent/AU771778B2/en not_active Ceased
- 2000-05-16 JP JP2000620944A patent/JP4884588B2/ja not_active Expired - Fee Related
- 2000-05-16 EP EP00935031A patent/EP1185272B1/en not_active Expired - Lifetime
- 2000-05-16 AT AT06017231T patent/ATE438399T1/de active
- 2000-05-16 PT PT00935031T patent/PT1185272E/pt unknown
- 2000-05-16 PL PL383406A patent/PL199650B1/pl unknown
- 2000-05-16 HU HU0201275A patent/HU229059B1/hu not_active IP Right Cessation
- 2000-05-16 CN CN200910113677A patent/CN101869565A/zh active Pending
- 2000-05-16 CZ CZ20014226A patent/CZ295623B6/cs not_active IP Right Cessation
- 2000-05-16 DK DK06017231T patent/DK1736158T3/da active
- 2000-05-16 UA UA2001128861A patent/UA74337C2/ru unknown
- 2000-05-16 CA CA002372668A patent/CA2372668C/en not_active Expired - Fee Related
- 2000-05-16 PT PT06017231T patent/PT1736158E/pt unknown
- 2000-05-16 SI SI200030902T patent/SI1410800T1/sl unknown
- 2000-05-16 CA CA2615271A patent/CA2615271C/en not_active Expired - Fee Related
- 2000-05-16 PT PT04001441T patent/PT1410800E/pt unknown
- 2000-05-16 SK SK1646-2001A patent/SK287851B6/sk not_active IP Right Cessation
- 2000-05-16 US US09/979,922 patent/US6900212B1/en not_active Expired - Lifetime
- 2000-05-16 DE DE60042710T patent/DE60042710D1/de not_active Expired - Lifetime
- 2000-05-16 EP EP04001441A patent/EP1410800B1/en not_active Expired - Lifetime
- 2000-05-16 PL PL352373A patent/PL199516B1/pl unknown
- 2000-05-16 DE DE60030338T patent/DE60030338T2/de not_active Expired - Lifetime
- 2000-05-16 CN CNB008081352A patent/CN1198618C/zh not_active Expired - Fee Related
- 2000-05-16 RU RU2001133342A patent/RU2237477C2/ru not_active IP Right Cessation
- 2000-05-16 TR TR2001/03361T patent/TR200103361T2/xx unknown
- 2000-05-16 ES ES00935031T patent/ES2219342T3/es not_active Expired - Lifetime
- 2000-05-16 BR BR0010948-7A patent/BR0010948A/pt not_active Application Discontinuation
- 2000-05-16 WO PCT/EP2000/004376 patent/WO2000072832A2/en active IP Right Grant
- 2000-05-16 DK DK04001441T patent/DK1410800T3/da active
- 2000-05-16 CN CNA2005100544177A patent/CN1679577A/zh active Pending
- 2000-05-16 SI SI200030423T patent/SI1185272T1/xx unknown
- 2000-05-16 DE DE60009697T patent/DE60009697T2/de not_active Expired - Lifetime
- 2000-05-16 IL IL14670700A patent/IL146707A0/xx active IP Right Grant
- 2000-05-16 AT AT00935031T patent/ATE263564T1/de active
- 2000-05-16 EP EP06017231A patent/EP1736158B1/en not_active Expired - Lifetime
- 2000-05-16 ES ES06017231T patent/ES2330774T3/es not_active Expired - Lifetime
- 2000-05-25 MY MYPI20002314A patent/MY135627A/en unknown
- 2000-05-26 AR ARP000102575A patent/AR024112A1/es unknown
-
2001
- 2001-11-22 IL IL146707A patent/IL146707A/en not_active IP Right Cessation
- 2001-11-26 NO NO20015746A patent/NO322120B1/no not_active IP Right Cessation
- 2001-12-20 ZA ZA200110485A patent/ZA200110485B/en unknown
-
2003
- 2003-01-23 HK HK03100617.0A patent/HK1048444B/zh not_active IP Right Cessation
-
2004
- 2004-11-23 US US10/994,226 patent/US7371756B2/en not_active Expired - Lifetime
-
2006
- 2006-04-06 NO NO20061562A patent/NO324230B1/no not_active IP Right Cessation
- 2006-11-02 CY CY20061101575T patent/CY1105750T1/el unknown
-
2007
- 2007-11-28 US US11/946,149 patent/US7642261B2/en not_active Expired - Fee Related
-
2009
- 2009-10-14 CY CY20091101063T patent/CY1109472T1/el unknown
- 2009-11-17 US US12/620,049 patent/US20100063062A1/en not_active Abandoned
-
2011
- 2011-02-10 JP JP2011027903A patent/JP2011148799A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2001133342A (ru) | Новое применение 1[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина и его физиологически приемлемых солей | |
| BR0010948A (pt) | Uso de 1-[4-(5-cianoindol-3-il)butil]-4-(2-carbamoil-benzofura n-5-il)-piperazina e seus sais fisiologicamente aceitáveis | |
| HRP20150371T1 (hr) | Supstituirani derivati 1,2,3,4-tetrahidroizokinolina | |
| NO2017063I1 (no) | Kombinasjon av: - rilpivirine hydroklorid etter en terapeutisk ekvivalent form derav, - emtricitabine og - tenofovir alafenamid eller farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamidfumarat | |
| LU92393I2 (fr) | Glycopyrronium ou un sel de celui-ci, plus particulièrement le sel bromure, combiné à indacatérol ouun sel de celui-ci, plus particulièrement le sel maléate | |
| NO20035120D0 (no) | 4-(fenyl-(piperidin-4-yl)-amino)-benzamidderivater og deres anvendelse vedbehandling av angst, smerte eller gastrointestinale forstyrrelser | |
| IL184125A (en) | Use of 3 - z - [- 1 - (4 - (n - ((4 - methyl - piperazine - 1 - yl) - methylcarbonyl) - n - methyl - amino) anilino) - 1 - phenyl - methylene] - 6 Methoxycarbonyl-2-indulinone for the preparation or prevention of osteopathic pulmonary fibrosis | |
| DE60234116D1 (de) | Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems | |
| RU2002114337A (ru) | 4-фенилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норадреналина, допамина и серотонина | |
| WO2002102794A3 (en) | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride | |
| NO20025221L (no) | Nytt preparat | |
| NO20012858D0 (no) | 4-(Aminometyl)-piperidin benzamider for behandling av gastrointestinale fortyrrelser | |
| CA2503718A1 (en) | Use of serotonin receptor antagonists for the treatment of sleep apnea | |
| ATE303379T1 (de) | 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| SE9900833D0 (sv) | Novel combination | |
| NO20051471L (no) | Piperidin-2,6-dionpamoatsalter og deres anvendelse for behandling av stressrelaterte affektforstyrrelser | |
| NO20035115D0 (no) | 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser | |
| NO20035117D0 (no) | 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser | |
| NO20035118D0 (no) | 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser | |
| JP2007511570A5 (ru) | ||
| BR0000486A (pt) | Antagonistas do neuropeptìdeo y | |
| NO20035114D0 (no) | 4-(fenyl-(piperidin-4-yl)-amino)-benzamidderivater og deres anvendelse vedbehandling av angst, smerte eller gastrointestinale forstyrrelser | |
| RU2003116893A (ru) | Новое применение объединенных агонистов 5-нт1а и ингибиторов обратного захвата серотонина | |
| NO20035113D0 (no) | 4-(fenyl-(piperidin-4-yl)-amino)-benzamidderivater og deres anvendelse vedbehandling av angst, smerte eller gastrointestinale forstyrrelser | |
| PL376713A1 (pl) | Zastosowanie pochodnych kwasu piperazynosulfonowego jako antagonistów CCR1 do leczenia zwłóknienia, choroby Alzheimera i innych zaburzeń |